Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Nicholas Henderson"'
Autor:
Hanna Cholé, Alice Merlin, Nicholas Henderson, Estelle Paupy, Prisca Mahé, Gérard Arnold, Jean-Christophe Sandoz
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-16 (2022)
Abstract In honeybees, the antennae are highly mobile sensory organs that express scanning movements in various behavioral contexts and toward many stimuli, especially odorants. The rules underlying these movements are still unclear. Using a motion-c
Externí odkaz:
https://doaj.org/article/a28a4c38fcc548bea55c0f0c51962571
Autor:
Harry J. Whitlow, Gyula Nagy, Nicholas Henderson, Richard Greco, Naresh Deoli, Karen M. Smith, Karen Morgan, Francois Villinger
Publikováno v:
Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms. 539:152-161
Autor:
Nicholas Borcherding, Kevin J. Severson, Nicholas Henderson, Luana S. Ortolan, Allison C. Rosenthal, Andrew M. Bellizzi, Vincent Liu, Brian K. Link, Aaron R. Mangold, Ali Jabbari
Publikováno v:
Blood Advances. 7:321-335
Cutaneous T-cell lymphomas (CTCLs) are a spectrum of diseases with varied clinical courses caused by malignant clonal proliferation of skin-tropic T cells. Most patients have an indolent disease course managed with skin-directed therapies. In contras
Publikováno v:
Biocomputing 2023.
The discovery of cancer drivers and drug targets are often limited to the biological systems - from cancer model systems to patients. While multiomic patient databases have sparse drug response data, cancer model systems databases, despite covering a
Autor:
Vadim S Koshkin, Nicholas Henderson, Deepak Kilari, Tanya Jindal, Omar Alhalabi, Dory Freeman, Arnab Basu, Pedro C. Barata, Mehmet Asim Bilen, Yousef Zakharia, Hamid Emamekhoo, Sumit Shah, Matthew I. Milowsky, Nancy B. Davis, Shilpa Gupta, Christopher J. Hoimes, Petros Grivas, Joaquim Bellmunt, Matthew T Campbell, Ajjai Shivaram Alva
Publikováno v:
Journal of Clinical Oncology. 41:514-514
514 Background: EV is FDA-approved in pts with aUC and ≥1 prior therapy line. Data from EV-103 trial indicate robust response to first-line EV/pembrolizumab, suggesting potentially at least additive treatment effect with EV/ICI combination. Given t
Autor:
Vadim S. Koshkin, Nicholas Henderson, Marihella James, Divya Natesan, Dory Freeman, Amanda Nizam, Christopher T. Su, Ali Raza Khaki, Chelsea K. Osterman, Michael J. Glover, Ryan Chiang, Dimitrios Makrakis, Rafee Talukder, Emily Lemke, T. Anders Olsen, Jayanshu Jain, Albert Jang, Alicia Ali, Tanya Jindal, Jonathan Chou, Terence W. Friedlander, Christopher Hoimes, Arnab Basu, Yousef Zakharia, Pedro C. Barata, Mehmet A. Bilen, Hamid Emamekhoo, Nancy B. Davis, Sumit A. Shah, Matthew I. Milowsky, Shilpa Gupta, Matthew T. Campbell, Petros Grivas, Guru P. Sonpavde, Deepak Kilari, Ajjai S. Alva
Publikováno v:
CancerReferences. 128(6)
Enfortumab vedotin (EV) is a novel antibody-drug conjugate approved for advanced urothelial cancer (aUC) refractory to prior therapy. In the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study, the authors looked at the exp
Autor:
Amanda R. Schwartz, Min Xu, Nicholas Henderson, Cynthia Dela Cruz, Daniel Pfau, Vasantha Padmanabhan, Ariella Shikanov, Molly B. Moravek
Publikováno v:
Fertility and Sterility. 118:e20
Autor:
Clara Hwang, Nicholas Henderson, Frank Cameron Cackowski, Amanda Pilling, Albert Jang, Shoshana Rothstein, Matthew Labriola, Joseph J. Park, Alyssa Ghose, Mehmet Asim Bilen, Deepak Kilari, Abhishek Tripathi, Rohan Garje, Vadim S Koshkin, Michael Thomas Schweizer, Andrew J. Armstrong, Rana R. McKay, Tanya B. Dorff, Ajjai Shivaram Alva, Pedro C. Barata
Publikováno v:
Journal of Clinical Oncology. 40:5013-5013
5013 Background: Black men have been underrepresented in large-scale molecular prostate cancer (PC) surveys, despite having higher PC incidence and mortality. Since molecular profiling to guide the use of targeted agents is increasingly important in
Publikováno v:
Fertility and Sterility. 116:e252-e253
Autor:
Zeynep Busra Zengin, Nicholas Henderson, Joseph J. Park, Alicia Ali, Clara Hwang, Pedro C. Barata, Mehmet Asim Bilen, Laura Graham, Deepak Kilari, Abhishek Tripathi, Matthew Labriola, Shoshana Rothstein, Rohan Garje, Vadim S Koshkin, Vaibhav G. Patel, Michael Thomas Schweizer, Andrew J. Armstrong, Rana R. McKay, Ajjai Shivaram Alva, Tanya B. Dorff
Publikováno v:
Journal of Clinical Oncology. 40:138-138
138 Background: AR alterations such as ligand binding domain mutations and amplification evolve under the selective pressure of testosterone suppression and AR targeted agents (ARTA) such as abiraterone or enzalutamide, but their relevance to ARTA tr